Weekly Recap | RxSight -5.57%, consensus target above spot
I'm LongbridgeAI, I can summarize articles.RxSight lost 5.57% this week to close at $6.02, underperforming the S&P 500 by about 4.77 percentage points (the benchmark fell 0.8%). The four-day session had a rally-then-fade shape: Tuesday closed near the weekly high at $6.45, Wednesday hit a peak of $6.655 before turning, Thursday gapped lower and settled at $5.96, and Friday traded in a narrow $5.78–$6.025 band to finish at $6.02. Weekly amplitude was 13.93%, and average daily volume came in roughly 9% below its prior median.
The Week
RxSight lost 5.57% this week to close at $6.02, underperforming the S&P 500 by about 4.77 percentage points (the benchmark fell 0.8%). The four-day session had a rally-then-fade shape: Tuesday closed near the weekly high at $6.45, Wednesday hit a peak of $6.655 before turning, Thursday gapped lower and settled at $5.96, and Friday traded in a narrow $5.78–$6.025 band to finish at $6.02. Weekly amplitude was 13.93%, and average daily volume came in roughly 9% below its prior median.
Key Events
No routine company news hit the wires this week; the main substantive development was a single filing. On Wednesday, 9 September, a SC TO-I/A was submitted, relating to a tender offer for RxSight as the subject company, under subject identifier 0001111485. The amended tender offer statement arrived one day after the stock set its weekly high of $6.655 on Wednesday, and the stock pulled back over the next two sessions. The filing and the price move share a timeline, but the data does not establish a causal link.
Analyst Ratings
Across the latest coverage, 10 firms rate the stock: 1 buy, 1 overweight, 7 hold and 2 underweight, with no sell ratings. The consensus rating is hold, and the consensus target price is $7.7875, about 29.36% above the latest price of $6.02. The target range is wide: the low of $6.00 sits almost in line with spot, while the high reaches $11.00, pointing to a clear split among brokers on valuation. Within the medical supplies industry, RxSight ranks 13th out of 35 covered names.
The Week Ahead
The macro calendar is busy next week. Tuesday, 15 September brings the New York Fed manufacturing index (prior 20.6, forecast 14.75). Wednesday, 16 September is the heavy day: retail sales (prior -0.6%, forecast 0.9%), retail sales ex-autos (prior -0.3%, forecast 0.6%), import prices, the NAHB housing market index (prior 35, forecast 34) and the EIA weekly crude inventory change. These readings will offer a fresh temperature check on US consumption and manufacturing.
In Short
RxSight’s tape was soft this week: the stock lagged the benchmark by close to five percentage points, average daily volume ran below its prior median, and the latest session showed almost zero large-lot inflow alongside zero large-lot outflow, with small-lot flows dominating volume. That suggests no directional big-money presence in the final session. At the same time, broker ratings lean neutral-to-positive: the consensus target sits about 29% above spot, but the target range is wide and the industry ranking is mid-table. What matters from here is whether the tender offer filing develops into a clearer fundamental catalyst, and whether next week’s retail sales and other macro prints support broader risk appetite.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.